A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Angioedema
Interventions
OTHER

Placebo

Placebo-matching lanadelumab SC injection.

DRUG

Lanadelumab

Lanadelumab solution in a PFS for injection.

Trial Locations (45)

1088

Semmelweis Egyetem, Budapest

4103

Universitaetsklinikum Leipzig AoeR, Leipzig

8035

Hospital Universitari Vall d'Hebron, Barcelona

8907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

20157

Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco), Milan

20815

Institute for Asthma & Allergy - Chevy Chase, Chevy Chase

28046

Hospital Universitario La Paz, Madrid

28277

Clinical Research of Charlotte, Charlotte

33613

University of South Florida Asthma, Allergy & Immunology, Tampa

35209

Clinical Research Center of Alabama, Birmingham

36312

Complexo Hospitalario Universitario de Vigo, Vigo

38043

CHU Grenoble Alpes, service de médecine interne, bureau de recherche clinique, Isere

43235

Optimed Research, LTD, Columbus

45231

Bernstein Clinical Research Center, LLC, Cincinnati

46026

Hospital Universitari i Politecnic La Fe, Valencia

48106

University of Michigan, Ann Arbor

48903

Hospital Universitario Cruces, Barakaldo

55131

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz

55905

Mayo Clinic - Rochester, Rochester

60590

Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt am Main

60612

Rush University Medical Center, Chicago

63141

Washington University, St Louis

66211

Kanarek Allergy, Asthma and Immunology, Overland Park

75012

Service médecine interne, hôpital Saint Antoine, Paris

80131

DAI di Medicina Interna, Immunologia Clinica, Patologia Clinica, Malattie Infettive, Napoli

80907

Asthma and Allergy Associates, PC, Colorado Springs

81675

Klinikum rechts der Isar der TUM, HNO Klinik und Poliklinik, Munich

84041

Tanner Clinic, Layton

84131

Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno

85248

Medical Research of Arizona, Scottsdale

90404

AIRE Medical of Los Angeles, Santa Monica

92122

University of California San Diego, San Diego

94598

Allergy and Asthma Clinical Research Inc, Walnut Creek

98115

Seattle Allergy & Asthma Research Institute, Seattle

02421

Massachusetts General Hospital, Boston

07410

Jay M Kashkin, MD Allergy, Asthma and Immunology, Fair Lawn

K1G 6C6

Ottawa Allergy Research Corporation, Ottawa

G1V 4W2

Clinique Specialisee en Allergie de la Capitale, Québec

734-8851

Hiroshima University Hospital, Hiroshima

650-0017

Kobe University Hospital, Hyōgo

1105 AZ

Amsterdam UMC, Amsterdam

9713 GZ

Universitair Medisch Centrum Groningen, Groningen

3508 GA

UMC Utrecht, Utrecht

15-867

NZOZ Homeo Medicus, Poradnia Alergologiczna, Bialystok

53-201

"ALL-MED Specjalistyczna Opieka Medyczna Medyczny Instytut Badawczy", Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY

NCT04206605 - A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) | Biotech Hunter | Biotech Hunter